Lead Sponsor

Ottawa Hospital Research Institute

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

No

•1. Infants born between 24+0 and 31+6 weeks gestational age, admitted to the study centers
•2. Infants with RDS requiring intubation and surfactant therapy within 48 hours after birth

•1. Any infant more than 48 hours of age
•2. Any infant with a pulmonary hemorrhage
•3. Any infant with life-threatening congenital anomaly or one that is considered non-viable
•4. Any infant on rescue high frequency ventilation
•5. Any infant known to require early intubation and ventilation for surgical treatment of a congenital anomaly
•6. Any infant with anomalies of the upper or lower airway or mandible precluding use of nCPAP
•7. Any infant born after prolonged premature rupture of membranes (\<22 weeks GA or \>28 days prior to delivery)
•8. A parent/LAR who is incapable of, or unwilling, to give consent
•9. Participation in another clinical trial of any placebo, drug, biological, or device conducted under the provisions of a protocol
•10. Any other reason as deemed significant by the Investigator

Related studies

NCT07261787 · Neonates and Preterm Infants, Infant Respiratory Distress Syndrome, and more

NCT07251790 · Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant

NCT06776783 · Respiratory Distress Syndrome, Pre-term Infants

NCT04565665 · COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, and more

NCT07514481 · Respiratory Distress Syndrome, Newborn

A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants